Thursday, July 25, 2013

AstraZeneca and Bristol-Myers resubmit NDA for Dapagliflozin for treatment of type 2 diabetes to USFDA

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

Enter your email address:


Delivered by FeedBurner